로딩 중…
StockDiggingStockDigging

Artivion, Inc.

AORT· NYSE
$23.31-2.39%
2026-09-18

Financials

Valuation Metrics

Artivion, Inc.'s Market Cap is $1.13B. At end of 2025 it was $2.17B. Ranked #2385 of 3,121 in US market (top 76%), #1420 of 1,658 on NYSE (top 86%), #149 of 205 in Health Care Equipment & Services (top 73%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.13B
Revenue$471M
Net Income$-3M
Total Assets$1.07B
Net Assets$446M
Employees1,800
Value
P/B2.54x
P/S2.40x
EV/EBITDA25.47x
FCF Yield-0.96%
Profitability
ROE-0.71%
ROA-0.30%
Op. Margin4.00%
Revenue Growth16.40%
Financial Health
Debt Ratio140.57%
Total Debt$408M
FCF$-11M
Cash$77M
Current Ratio3.47x
Net Debt/EBITDA5.76x
Performance
1Y Return-43.64%
1M Return-19.12%
From 52W High-51.69%
1Y MDD-57.80%
Trading
Volume518,648 shares
Trading Value$12M
Per Share
EPS$-0.07
BPS$9.18

Company Info

CEO Mr. James Patrick Mackin
Employees 1,800
HQ Kennesaw, United States

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.